Enzyme–substrate reporters for evaluation of substrate specificity of HIF prolyl hydroxylase isoforms
- Авторлар: Osipyants A.1, Smirnova N.1, Khristichenko A.1, Hushpulian D.1, Nikulin S.1, Chubar T.2, Zakhariants A.3, Tishkov V.2,3, Gazaryan I.1,2, Poloznikov A.1
-
Мекемелер:
- Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
- Lomonosov Moscow State University, Chemistry Faculty
- Innovations and High Technologies MSU Ltd.
- Шығарылым: Том 82, № 10 (2017)
- Беттер: 1207-1214
- Бөлім: Article
- URL: https://journals.rcsi.science/0006-2979/article/view/151491
- DOI: https://doi.org/10.1134/S0006297917100145
- ID: 151491
Дәйексөз келтіру
Аннотация
An organism naturally responds to hypoxia via stabilization of hypoxia-inducible factor (HIF). There are three isoforms of HIFα subunits whose stability is regulated by three isozymes of HIF prolyl hydroxylase (PHD1-3). Despite intense studies on recombinant enzyme isoforms using homogeneous activity assay, there is no consensus on the PHD iso-form preference for the HIF isoform as a substrate. This work provides a new approach to the problem of substrate specificity using cell-based reporters expressing the enzyme and luciferase-labeled substrate pair encoded in the same expression vector. The cell is used as a microbioreactor for running the reaction between the overexpressed enzyme and substrate. Using this novel approach, no PHD3 activity toward HIF3 was demonstrated, indirectly pointing to the hydroxylation of the second proline in 564PYIP567 (HIF1) catalyzed by this isozyme. The use of “paired” enzyme–substrate reporters to evaluate the potency of “branched tail” oxyquinoline inhibitors of HIF PHD allows higher precision in revealing the optimal structural motif for each enzyme isoform.
Негізгі сөздер
Авторлар туралы
A. Osipyants
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
N. Smirnova
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
A. Khristichenko
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
D. Hushpulian
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
S. Nikulin
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
T. Chubar
Lomonosov Moscow State University, Chemistry Faculty
Email: igazaryan@gmail.com
Ресей, Moscow, 119991
A. Zakhariants
Innovations and High Technologies MSU Ltd.
Email: igazaryan@gmail.com
Ресей, Moscow, 109451
V. Tishkov
Lomonosov Moscow State University, Chemistry Faculty; Innovations and High Technologies MSU Ltd.
Email: igazaryan@gmail.com
Ресей, Moscow, 119991; Moscow, 109451
I. Gazaryan
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology; Lomonosov Moscow State University, Chemistry Faculty
Хат алмасуға жауапты Автор.
Email: igazaryan@gmail.com
Ресей, Moscow, 117997; Moscow, 119991
A. Poloznikov
Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
Email: igazaryan@gmail.com
Ресей, Moscow, 117997
![](/img/style/loading.gif)